ALS Worldwide welcomes any questions or comments you might have.  We provide free, personalized and confidential support services to anyone in the ALS community—whether you are a patient or a loved one, friend, health care professional or caregiver of someone diagnosed.

Get help now! Fill out the Online Profile Form or if you would prefer to talk with someone by email or phone first, please contact us at [email protected] or 1-414-831-6879.

For all other inquiries, please use the email form to the right and we will respond promptly to your request.Thank you.

ALS Worldwide
1800 North Prospect Avenue, Suite 4B
Milwaukee, WI 53202

ALS Worldwide
July 10, 2017

More results are in! Edavone shown to provide greater benefits to ALS patients after one year

"Data from the open-label extension trial of Edaravone (Radicava) in patients with ALS demonstrated the drug continued to provide benefits after 48 weeks of treatment. These findings were presented by researchers from MT Pharma America, the company which manufactures Edaravone, at the May 18-20 European Network for the Cure of ALS (ENCALS) Annual Meeting.

'The 12-month data presented at ENCALS suggest early intervention with Radicava may lead to a meaningful clinical benefit when promptly initiated in people with ALS, as opposed to being delayed by six months,' Dr. Jean Hubble, vice-president for medical affairs at MT Pharma America, said in a press release.

The trial extension compared patients who had taken Radicava for 48 weeks to those treated with placebo for six months in the original Phase 3 trial, before switching to Radicava for another 24 weeks in the open-label study. Measurements of the ALS Functional Rating Scale-Revised (ALSFRS-R) showed that those who received Radicava for the full 48 weeks had significantly less physical decline and an about 58 percent lower relative risk of death or certain disease progression events."

Read the full article entitled Radicava Upholds Benefits

ALS Worldwide is in agreement with MT Pharma's findings, based upon observations and results from our edaravone compassionate usage with patients over the past year. Our supervision of these trials suggests the benefits of edaravone occur, to a somewhat but still very meaningful level, in patients of greater than one year duration of disease WHEN BEGINNING the protocol. Further, patient benefit continues AFTER a one-year period of using Edaravone. Results showed the positive impact of the drug to be greater after one year of use as opposed to near the beginning of the trial. The drug appears beneficial for an indefinite period of time.

FDA approved Edaravone for ALS on May 7. To learn more about the FDA approval, please visit: Edavavone

We will continue to monitor and report all updates on Edaravone and its use for ALS patients, and we hope the results continue to show great promise and hope for all in the ALS community.